|Bid||176.80 x 0|
|Ask||177.40 x 0|
|Day's range||176.60 - 185.72|
|52-week range||154.00 - 224.50|
|Beta (5Y monthly)||0.30|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|Ex-dividend date||20 Jun 2019|
|1y target est||N/A|
When it comes to researching shares, many investors take note of what city analysts have to say. The trading recommendations of these professionals are used by...
On Wednesday we chose a healthcare company as our stock tip of the year, on the basis not only of our expectations of its own recovery but because of investors’ recent aversion to the sector as a whole. We will double down on that belief today and pick our investment trust of the year from the same arena.
Gyroscope's parent company, London-listed healthcare investment firm Syncona Ltd, said on Wednesday that Novartis will pay $800 million upfront and up to $700 million in additional milestone payments. Gyroscope's treatment for geographic atrophy, a disease of the retina that leads to blindness and for which there is currently no treatment, is in the second phase of clinical development. Gene therapies are currently among the world's most expensive drugs.